Regulatory Toxicology and Pharmacology | |
Discipline: | Toxicology and pharmacology |
Abbreviation: | Regul. Toxicol. Pharmacol. |
Publisher: | Elsevier on behalf of the International Society of Toxicology & Pharmacology |
Frequency: | Monthly |
History: | 1981–present |
Impact: | 3.271 |
Impact-Year: | 2021 |
Website: | http://www.journals.elsevier.com/regulatory-toxicology-and-pharmacology/ |
Link1: | http://www.sciencedirect.com/science/journal/02732300 |
Link1-Name: | Online access |
Oclc: | 485750423 |
Lccn: | 81646304 |
Coden: | RTOPDW |
Issn: | 0273-2300 |
Regulatory Toxicology and Pharmacology is a monthly peer-reviewed scientific journal which covers legal aspects of toxicological and pharmacological regulations. It is published by Elsevier on behalf of the International Society of Regulatory Toxicology & Pharmacology. The current co-editors-in-chief are Lesa L. Aylward and Martin van den Berg.
In 2002, a group of 45 academics wrote a letter accusing the journal of a concealed pro-industry bias, a possible lack of full and independent peer review, and a failure to disclose conflicts of interest, citing a case in which Gio Batta Gori, then-current editor-in-chief, was paid $30,000 by the Tobacco Institute to write an article later published in the journal dismissing the health risks of secondhand smoke.[1] [2] The letter's coordinator later commented that the journal "reads like an industry trade publication, but it's masked as a peer-reviewed journal" and that it lacked any "credible peer-review process."[3] In response, the journal's publisher implemented a conflict of interest disclosure policy at the journal in January 2003, shortly before the correspondence was published.[1]
The journal is abstracted and indexed in EMBASE, EMBiology, and Scopus.
According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.031, ranking it 56th out of 87 journals in the category "Toxicology"[4] and 146th out of 254 journals in the category "Pharmacology & pharmacy".[5]